Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study
28/10/2022 07:07
Oct 28 (Reuters) - Quantum Genomics SA ALQGC.PA :
* QUANTUM GENOMICS ANNOUNCES LACK OF SIGNIFICANT EFFICACY
FOR
FIRIBASTAT IN THEIR PHASE III STUDY, FRESH AND IS REDIRECTING TO
NEW DEVELOPMENTS
Source text for Eikon: ID:nACT76960
Further company coverage: ALQGC.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study